Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants with Pathologically Confirmed Cancer Refractory to Conventional Therapy

NCT05990920 is registered in ClinicalTrials.gov with NKGen Biotech, Inc. as lead sponsor.

NCT NCT05990920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05990920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants with Pathologically Confirmed Cancer Refractory to Conventional Therapy
Lead sponsor
NKGen Biotech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2023
Completion date
April 12, 2024
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, metastatic cancer, pathologically confirmed cancer refractory to conventional therapy, recurrent cancer, refractory cancer, solid tumor, solid tumor, adult